I will be going back to Okinawa shortly for another workshop in support of the Okinawa Institute of Science and Technology’s goal of developing an R&D cluster in Okinawa.
I really enjoy the opportunity to contribute to this initiative — Okinawa is a technologically-underdeveloped prefecture within a very technological developed country (Japan), so the expectations and available levels of support are far greater than those in other similarly underdeveloped regions. But, advancing Okinawa’s R&D capacity is not a simple matter of cash infusions or simple policy changes. Interventions must be directed at the unique challenges and opportunities within Okinawa, and must be tempered to Okinawa’s capacity to absorb them — you cannot create an R&D cluster overnight.
A summary of public portion of the first workshop is available on OIST’s site, and my thoughts were posted in the Journal of Commercial Biotechnology.
I look forward to this next workshop, and to sharing my perspectives on it.
The July issue of the Journal of Commercial Biotechnology will be distributed for free at BIO 2012 in Boston this summer.
This free, expanded, distribution is a great opportunity for authors and advertisers.
The Journal of Commercial Biotechnology, in print since 1994, is the definitive international quarterly publication for bioscience business professionals. The Journal is designed specifically for those professionals who need to enhance their knowledge of biotechnology business strategy and management, improve and advance their product development or want to keep up-to-date with current issues and industry trends.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
The submission deadline is April 2012. Please check out the sample papers, editorial policies, and submission guidelines. Feel free to contact me at email@example.com with any ideas for papers.
Ad specs are 8.25 x 10.75 in full color. Contact firstname.lastname@example.org for rates and availability.
DrugPatentWatch has updated its pharmaceutical patent intelligence reports, profiling profile patent challenges, orphan drugs, and leading inventors.
The following reports have been updated for 2012 and are now available through the DrugPatentWatch.com report store at http://www.DrugPatentWatch.com/reports:
DRUG PATENT CHALLENGE REPORT
– The Drug Patent Challenge Report profiles the companies that successfully challenged pharmaceutical drug patents since 2000.
ORPHAN DRUG REPORT
– The Orphan Drug Report profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity since 2000.
DRUG PATENT INVENTOR REPORTS
– The Drug Patent Inventor Reports profile the individuals who have been awarded pharmaceutical drug patents since 2000.
Individual country profiles are available for:
- South Korea
– United Kingdom
– United States
For complete details, see the DrugPatentWatch.com store at http://www.DrugPatentWatch.com/reports
I’m looking for people who are comfortable with video production and are into biotechnology. If that’s you (or someone you know), please drop me a line.
Get a free DrugPatentWatch Report
As a special bonus for BiotechBlog readers, you can get a free DrugPatentWatch report when you sign up for a one-year Ultimate Plan or Premium Plan subscription by January 29, 2012.
The following reports are available through this special offer:
|Drug Patent Challenge Report|
The Drug Patent Challenge Report profiles the companies that successfully challenged pharmaceutical drug patents since 2000.
- The companies with the most successful patent challenges
- The drugs for which each firm successfully challenged a patent
- The companies that have received FDA approval for each listed drug
- More than 60 companies profiled
- More than 80 drugs profiled
Currently selling for $800 in the DrugPatentWatch Report Store.
|Orphan Drug Report|
The Orphan Drug Report profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity since 2000.
- The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug
- Details on each NDA and product number, including Dosage, Strength, Approval Date, Therapeutic Equivalence (TE) code, Reference Listed Drug (RLD) indicator
- All FDA-listed patents covering each Orphan Drug
- More than 100 pages
- More than 80 drugs profiled
Currently selling for $500 in the DrugPatentWatch Report Store.
|Individual Country Drug Patent Inventor Reports|
These Individual Country Drug Patent Inventor Reports profile the individuals who have been awarded pharmaceutical drug patents since 2000.
Individual country profiles available for:
- South Korea
- United Kingdom
- United States
These reports currently sell for $195 to $795 in the DrugPatentWatch Report Store.
To take advantage of this offer:
Biotechnology company management presents several challenges relative to other industries. Firstly, many biotechnology managers come from scientific backgrounds and find their way into management positions with little formal management training. Secondly the tenure of managers may be short, and movement to new companies can bring new responsibilities, a different corporate culture, and a different external environment. Finally, the biotechnology industry is in a state of flux, with health care reform, pricing pressures, and the combined forces of globalization, offshoring, and increased outsourcing. So, it is with great interest that I read Practical Leadership for Biopharmaceutical Executives.
Author Jane Chin has a diverse background as founder and president of the Medical Science Liaison Institute, as managing partner in a management consulting firm, and with a certificate in competitive intelligence. In writing the book, Chin arranged it into seven chapters, each of which is presented in the style of a journal paper, complete with abstract and keywords. The book is primarily directed at middle and upper level management, and is also intended to serve a larger audience of organizational development consultant, C and E level executives, venture capitalists, and students. The chapters cover leadership as a phenomenon; management leadership competencies; presence, stewardship, and development; self-concept as a leader; and, a new model for pharmaceutical leadership.
While I applaud Chin’s definition of the role and responsibilities of leaders, I fear that the book does not serve the audience the jacket copy describes as its target. The introduction, for example, describes the methodology and conclusions of a study of biopharmaceutical executive leadership themes which is comprised of an analysis of 50,000 words transcribed from interview notes. It is excellent material, but seems better suited to a management journal than to a book. The remaining chapters follow a similar style, describing case studies and frameworks focused on biopharmaceutical management. The dense academic style of this book seems best suited to high-level specialized students and to career coaches and human resource professionals — those who manage managers.
Looking for biotechnology industry reference information? You could hop on the Internet and search among the myriad sites, figure out which ones are credible, then try and find a consensus, or you could grab a copy of Plunkett’s Biotech & Genetics Industry Almanac. This book is essentially a reference librarian in a box. I reviewed an earlier issue of this book several years ago (my endorsement is on the front cover), so I wondered how useful it might remain despite the advancement of search engines and new web resources. In short, I think the book is still very valuable.
Plunkett’s Almanac profiles the top companies and has statistics and trends in the areas of genomics, proteomics, biopharmaceuticals, research, business development, and commercialization. The book is split into several sections:
- A biotechnology and genetics industry glossary
- Major Trends Affecting the Biotech & Genetics Industry
- Biotech & Genetics Industry Statistics
- Important Biotech & Genetics Industry Statistics
- Profiles of Plunkett’s “Biotech 350″
At > 500 pages, the book represents a significant resource. A great deal of effort has gone into selecting valuable information and assembling it into a useful, objective, format. I recommend this book for biotechnology service firms needing the indexes of companies and knowledge of major trends, as well as for individuals in finance, market research, or other broad industry roles.
Drug Patent Expirations in January 2012
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number||Patent Expiration|
|VITRASERT||Bausch And Lomb||ganciclovir||5,378,475||Jan 3, 2012|
|LUNESTA||Sunovion Pharms Inc||eszopiclone||6,319,926||Jan 16, 2012|
|LUNESTA||Sunovion Pharms Inc||eszopiclone||7,381,724||Jan 16, 2012|
|PREFEST||Teva Womens||estradiol; norgestimate||5,382,573||Jan 17, 2012|
|VIDEX||Bristol Myers Squibb||didanosine||5,880,106*PED||Jan 22, 2012|
|OCTREOSCAN||Mallinckrodt||indium in-111 pentetreotide kit||5,384,113||Jan 24, 2012|
|TASMAR||Valeant Pharm Intl||tolcapone||5,236,952||Jan 29, 2012|
|PROTOPIC||Astellas||tacrolimus||5,385,907||Jan 31, 2012|
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.
Courtesy of DrugPatentWatch.com